INVIVYD, INC. Earnings Per Share (Basic)
INVIVYD, INC. (IVVD) reported Earnings Per Share (Basic) of -$0.14 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-13
- INVIVYD, INC. earnings per share, basic for the quarter ending 2026-06-30 was -$0.14.
- INVIVYD, INC. earnings per share, basic for the quarter ending 2026-03-31 was -$0.13.
- INVIVYD, INC. earnings per share, basic for the quarter ending 2025-12-31 was -$0.04.
- INVIVYD, INC. earnings per share, basic for the quarter ending 2025-09-30 was -$0.06.
- INVIVYD, INC. earnings per share, basic for fiscal 2025 was -$0.30.
- INVIVYD, INC. earnings per share, basic for fiscal 2024 was -$1.43.
- INVIVYD, INC. earnings per share, basic for fiscal 2023 was -$1.81.
- INVIVYD, INC. earnings per share, basic for fiscal 2022 was -$2.23.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$0.14 10-Q · filed 2026-08-13 | -$0.27 10-Q · filed 2026-08-13 | -$0.32 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$0.40 derived: net income ÷ weighted average shares · filed 2026-08-13 |
| 2026-03-31 | -$0.13 10-Q · filed 2026-05-14 | -$0.18 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$0.25 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$0.35 derived: net income ÷ weighted average shares · filed 2026-08-13 |
| 2025-12-31 | -$0.04 derived: net income ÷ weighted average shares · filed 2026-03-05 | -$0.10 derived: net income ÷ weighted average shares · filed 2026-03-05 | -$0.19 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$0.30 10-K · filed 2026-03-05 |
| 2025-09-30 | -$0.06 10-Q · filed 2025-11-06 | -$0.17 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$0.30 10-Q · filed 2025-11-06 | -$0.45 derived: net income ÷ weighted average shares · filed 2026-08-13 |
| 2025-06-30 | -$0.12 10-Q · filed 2026-08-13 | -$0.26 10-Q · filed 2026-08-13 | -$0.41 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$0.92 derived: net income ÷ weighted average shares · filed 2026-08-13 |
| 2025-03-31 | -$0.14 10-Q · filed 2026-05-14 | -$0.29 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$0.80 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$1.19 derived: net income ÷ weighted average shares · filed 2026-08-13 |
| 2024-12-31 | -$0.15 derived: net income ÷ weighted average shares · filed 2026-03-05 | -$0.66 derived: net income ÷ weighted average shares · filed 2026-03-05 | -$1.06 derived: net income ÷ weighted average shares · filed 2026-03-05 | -$1.43 10-K · filed 2026-03-05 |
| 2024-09-30 | -$0.51 10-Q · filed 2025-11-06 | -$0.90 derived: net income ÷ weighted average shares · filed 2025-11-06 | -$1.28 10-Q · filed 2025-11-06 | -$1.94 derived: net income ÷ weighted average shares · filed 2025-11-06 |
| 2024-06-30 | -$0.40 10-Q · filed 2025-08-14 | -$0.77 10-Q · filed 2025-08-14 | -$1.43 derived: net income ÷ weighted average shares · filed 2025-11-06 | -$1.79 derived: net income ÷ weighted average shares · filed 2025-11-06 |
| 2024-03-31 | -$0.38 10-Q · filed 2025-05-15 | -$1.04 derived: net income ÷ weighted average shares · filed 2025-11-06 | -$1.40 derived: net income ÷ weighted average shares · filed 2025-11-06 | -$1.86 derived: net income ÷ weighted average shares · filed 2025-11-06 |
| 2023-12-31 | -$0.67 derived: net income ÷ weighted average shares · filed 2025-03-20 | -$1.03 derived: net income ÷ weighted average shares · filed 2025-03-20 | -$1.49 derived: net income ÷ weighted average shares · filed 2025-03-20 | -$1.81 10-K · filed 2025-03-20 |
| 2023-09-30 | -$0.36 10-Q · filed 2024-11-14 | -$0.82 derived: net income ÷ weighted average shares · filed 2024-11-14 | -$1.14 10-Q · filed 2024-11-14 | -$1.55 derived: net income ÷ weighted average shares · filed 2024-11-14 |
| 2023-06-30 | -$0.46 10-Q · filed 2024-08-14 | -$0.78 10-Q · filed 2024-08-14 | -$1.19 derived: net income ÷ weighted average shares · filed 2024-11-14 | -$1.61 derived: net income ÷ weighted average shares · filed 2024-11-14 |
| 2023-03-31 | -$0.32 10-Q · filed 2024-05-09 | -$0.74 derived: net income ÷ weighted average shares · filed 2024-11-14 | -$1.15 derived: net income ÷ weighted average shares · filed 2024-11-14 | -$1.62 derived: net income ÷ weighted average shares · filed 2024-11-14 |
| 2022-12-31 | -$0.41 derived: net income ÷ weighted average shares · filed 2024-03-28 | -$0.83 derived: net income ÷ weighted average shares · filed 2024-03-28 | -$1.30 derived: net income ÷ weighted average shares · filed 2024-03-28 | -$2.23 10-K · filed 2024-03-28 |
| 2022-09-30 | -$0.42 10-Q · filed 2023-11-09 | -$0.89 derived: net income ÷ weighted average shares · filed 2023-11-09 | -$1.82 10-Q · filed 2023-11-09 | -$2.58 derived: net income ÷ weighted average shares · filed 2024-02-09 |
| 2022-06-30 | -$0.47 10-Q · filed 2023-08-10 | -$1.40 10-Q · filed 2023-08-10 | -$2.16 derived: net income ÷ weighted average shares · filed 2024-02-09 | -$3.05 derived: net income ÷ weighted average shares · filed 2024-02-09 |
| 2022-03-31 | -$0.93 10-Q · filed 2023-05-11 | -$1.69 derived: net income ÷ weighted average shares · filed 2024-02-09 | -$2.63 derived: net income ÷ weighted average shares · filed 2024-02-09 | -$4.14 derived: net income ÷ weighted average shares · filed 2024-02-09 |
| 2021-12-31 | -$0.76 derived: net income ÷ weighted average shares · filed 2024-02-09 | -$1.68 derived: net income ÷ weighted average shares · filed 2024-02-09 | -$3.30 derived: net income ÷ weighted average shares · filed 2024-02-09 | -$5.32 8-K · filed 2024-02-09 |
| 2021-09-30 | -$0.98 10-Q · filed 2022-11-10 | -$3.41 derived: net income ÷ weighted average shares · filed 2022-11-10 | -$7.06 10-Q · filed 2022-11-10 | |
| 2021-06-30 | -$178.86 10-Q · filed 2022-08-15 | -$663.94 10-Q · filed 2022-08-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |